Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Aro Biotherapeutics logo —

Aro Biotherapeutics

Founded 2018 United States Philadelphia, United States 51 employees Series B Total: $166.50M Biotechnology, Health Care +2

General Information

Company Name Aro Biotherapeutics
Founded Year 2018
Location United States Philadelphia, United States
Founders / Decision Makers
Team member Team member Team member
Employees 51
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series B
Business Model B2B, Platform, B2B2B
Revenue Model Licensing, Product Sales, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Aro Biotherapeutics. To contact Aro Biotherapeutics, visit arobiotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aro Biotherapeutics compare?

A PDF of Aro Biotherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aro Biotherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aro Biotherapeutics

Aro Biotherapeutics, founded in 2018 and headquartered in the United States, is at the forefront of biotechnology innovation. The company specializes in developing tissue-targeted genetic medicines, leveraging its proprietary Centyrins technology. This platform is propelling the creation of a robust pipeline of therapeutic candidates, addressing a wide spectrum of diseases through targeted delivery.

The recent $41.50M Series B investment on 01 November 2023 underscores the confidence prominent investors have in Aro's unique approach. The funding round was led by notable entities such as Johnson & Johnson Innovation, HealthCap, BVF Partners, Northpond Ventures, and Cowen Group. This financial backing is expected to accelerate the advancement of Aro's pipeline and foster enhanced collaborations with industry partners.

Positioned in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries, Aro Biotherapeutics presents a compelling opportunity for investors seeking to support groundbreaking advancements in genetic medicine.

Business keywords: genetic medicines, tissue-targeted therapies, Philadelphia, Centyrins, therapeutic candidates, proprietary protein technology, disease therapies, drug development, biopharmaceuticals, industry partnerships, disease targeting, genetic medicine innovation

Services & Products

Development of Centyrin-based Therapeutic Candidates
Research and Optimization of Receptor-specific Centyrins
Conjugation of Centyrins to Oligonucleotides

Target Customers

Patients with Genetic Disorders Biotechnology Industry Partners Researchers in Genetic Medicine

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $41.50M 5
Johnson & Johnson Innovation HealthCap BVF Partners
Johnson & Johnson Innovation, HealthCap +3
01 Nov 2023
Series B $24.00M 1
Cowen Group
01 Jan 2023
Series A $88.00M 8
Johnson & Johnson Innovation HealthCap BioMotiv
Johnson & Johnson Innovation, HealthCap +6
01 Jan 2021
Early VC $13.00M 2
Johnson & Johnson Innovation BioMotiv
Johnson & Johnson Innovation, BioMotiv
01 Dec 2018

Aro Biotherapeutics Alternatives & Competitors

View All Alternatives
Aro Biotherapeutics vs
Rgenta Therapeutics Inc.
Rgenta Therapeutics Inc. United States

We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecul...

Series A
33 employees
Biotechnology, Health Care
Compare Aro Biotherapeutics vs Rgenta Therapeutics Inc.
Aro Biotherapeutics vs
Nitrase Therapeutics
Nitrase Therapeutics United States

Pioneering Nitrase Biology and Medicines

Series A
13 employees
Biotechnology, Health Care
Compare Aro Biotherapeutics vs Nitrase Therapeutics
Aro Biotherapeutics vs
BreezeBio
BreezeBio United States

Genetic Medicine Delivered

Series A
65 employees
Biotechnology, Health and Wellness
Also compare with: Aro Biotherapeutics vs Aera Therapeutics Aera Therapeutics Aro Biotherapeutics vs Laronde Laronde View all alternatives

FAQ About Aro Biotherapeutics

Aro Biotherapeutics was founded in 2018.
Aro Biotherapeutics is headquartered in Philadelphia, United States.
Aro Biotherapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on genetic medicines, tissue-targeted therapies, Philadelphia and Centyrins. Its customers include Patients with Genetic Disorders, Biotechnology Industry Partners and Researchers in Genetic Medicine.
Aro Biotherapeutics has a B2B, Platform and B2B2B business model. Its revenue comes from Licensing, Product Sales and Project Based.
Aro Biotherapeutics has approximately 51 employees.
Aro Biotherapeutics has completed 4 funding rounds, raising a total of $166.50M. The latest funding stage is Series B.
Aro Biotherapeutics offers: Development of Centyrin-based Therapeutic Candidates, Research and Optimization of Receptor-specific Centyrins, Conjugation of Centyrins to Oligonucleotides.
Top alternatives and competitors to Aro Biotherapeutics include Rgenta Therapeutics Inc., Nitrase Therapeutics, BreezeBio, Orum Therapeutics, Versameb AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aro Biotherapeutics and Rgenta Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aro Biotherapeutics, https://bouncewatch.com/company/aro-biotherapeutics, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout